Basel / Fair Lawn, 9 May 2003. Lonza Ltd and Lonza Inc, subsidiaries of Lonza Group Ltd, announce the settlement of their recently filed patent infringement actions against Barrington Chemical Corp., Carnitech, Inc and Nutritional Sourcing International, Inc in the District Court for the Southern District of New York.
As part of the settlement, Barrington, Carnitech, NSI and NSI Leaders Nutrition, admitted the validity of and agreed to refrain from infringing Lonza’s Carnitine patents, for the use in swine, poultry and racing animals and for L-Carnitine L-Tartrate used as a dietary supplement and covered by US Patent No. 5,073,376. The subject patent specifically covers enteric preparations (solid oral dosage forms) of L-Carnitine LTartrate in tablet, capsule and powdered form, and the making and using of such preparations.
Lonza is an industry leader in developing innovative technology on the nutritional uses of L-Carnitine and has an extensive patent portfolio covering these advances. Reto Rieder, Global Director for Nutrition Products at Lonza said: “We have started to take legal action against patent violators and will vigorously defend our intellectual property rights in the future as well”. These lawsuits and their favorable settlements are a significant step in protecting Lonza’s intellectual property rights.
Lonza Biotec is focused on microbial fermentation and is the leader in process development and custom manufacturing of therapeutic ingredients and intermediates based on its 20 years of experience. Lonza Biotec undertakes manufacturing services for the pharmaceutical, biotechnology and nutrition industries. With headquarters in Basel (Switzerland), Lonza Biotec operates R&D and cGMP multi-product manufacturing facilities in Visp (Switzerland) and Kourim (Czech Republic).
Lonza is a Life Sciences driven company headquartered in Switzerland, with sales of CHF 2.54 billion in 2002 and operating 18 production and R&D facilities in 8 countries. It employs 6 200 people worldwide and is the leading custom manufacturer of active chemical ingredients, intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. It also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymerintermediates and compounds. For more information on Lonza please visit the company’s website at www.lonza.com.
For further information please contact:
Communications & Investor Relations
Tel +41 61 316 8363
Fax +41 61 361 8220